Mankind Pharma's net profit surged 29% to Rs 659 cr in Q2 FY25, driven by volume recovery and strong EBITDA margins. Revenue ...

Pharmaceutical firm Mankind Pharma Ltd on Tuesday (November 5) reported a 30.4% year-on-year (YoY) jump in net profit at ₹653 ...

The company reported a stronger-than-expected profit, driven by high demand for its drugs for chronic conditions such as ...

Mankind Pharma Q2 Results: Mankind Pharma on Tuesday reported a 29 per cent rise in its consolidated net profit to Rs 658.88 ...

India's Mankind Pharma reported a better-than-expected second-quarter profit on Tuesday, driven by strong demand for its drugs to treat long-term illnesses, such as diabetes and cardiovascular ...

Last week, Torrent Pharma missed second-quarter profit estimates, hurt by the shutdown of an insulin manufacturing facility.

Mankind Pharma on Tuesday reported that its consolidated net profit increased 29% in the second quarter of fiscal 2025. The company posted a net profit of Rs 658.88 crore in the quarter ended Sept. 30 ...

India's Mankind Pharma reported a stronger-than-expected profit for the second quarter of FY24, driven by higher demand for its medications targeting long-term health conditions like diabetes and ...

Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

The Board of Directors of Mankind Pharma Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 FY2024-25.

Revenue contribution from Mankind Pharma's mainstay chronic illness drugs segment climbed to 35% from 34%, driving total revenue 14% higher ...